DBV Technologies S.A.
HealthcareNASDAQ:DBVT · NASDAQ Global Select
+$0.88 today
Vol 0.99M · Avg 0.24M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-87.1%
avg -103.7%
ROIC
-76.6%
avg -88.6%
ROA
-62.9%
avg -64.3%
Analysis
ROA is currently the strongest return metric at -62.9% versus its period average of -64.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel Tassé | Chief Executive Officer & Director | $1.44M | — | 66 | $964,000.00 | 4.03% |
Pharis Mohideen | Chief Medical Officer | $1.02M | — | 61 | $144,995.00 | 0.61% |
Virginie Simone Jeanine Verrechia Boucinha | Chief Financial Officer | $600,144.00 | — | 57 | $70,000.00 | 0.29% |
Alan Kerr | Senior Vice President & Head of Global Regulatory Affairs | — | — | — | — | — |
Kevin Malobisky | Chief Operations Officer | — | — | — | $55,000.00 | 0.23% |
James Briggs | Chief Human Resources Officer | — | — | 54 | — | — |
Jonathan Neely | VP & Head of Investor Relations | — | — | — | — | — |
Kevin Trapp | Chief Commercial Officer | — | — | 59 | $55,000.00 | 0.23% |
Pascal Wotling | Chief External Manufacturing & Supply Chain Officer | — | — | — | — | — |
Michele F. Robertson | Chief Legal Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
7
$15.51M
Net Sentiment
$15.51M
Net selling
Most Active
Mohideen Pharis
4 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 7 sells worth $15.51M over the last 12 months. That adds up to net selling of $15.51M. Mohideen Pharis was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -1.4% | +78.4% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at -1.4% over three years. Forward estimates point to Revenue at +78.4% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
LB Pharmaceuticals Inc Common Stock
NASDAQ:LBRX
$814.99M
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
Annexon, Inc.
NASDAQ:ANNX
$563.29M
Lexeo Therapeutics, Inc. Common Stock
NASDAQ:LXEO
$343.14M
Amarin Corporation plc
NASDAQ:AMRN
$315.21M
Cellectis S.A.
NASDAQ:CLLS
$310.29M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
Altimmune, Inc.
NASDAQ:ALT
$230.35M
Korro Bio, Inc.
NASDAQ:KRRO
$115.56M
enGene Holdings Inc.
NASDAQ:ENGN
$82.94M
Who manages DBVT?
DBV Technologies S.A. (DBVT) lists 10 active executives. The top listed executive is Alan Kerr, Senior Vice President & Head of Global Regulatory Affairs.
Are DBVT insiders buying or selling?
Recent insider activity shows net selling of $24.79M.
Explore More
Continue the stock analysis
Jump to another research area for this company.